DE602007008553D1 - Verwendung von organischen verbindungen - Google Patents

Verwendung von organischen verbindungen

Info

Publication number
DE602007008553D1
DE602007008553D1 DE602007008553T DE602007008553T DE602007008553D1 DE 602007008553 D1 DE602007008553 D1 DE 602007008553D1 DE 602007008553 T DE602007008553 T DE 602007008553T DE 602007008553 T DE602007008553 T DE 602007008553T DE 602007008553 D1 DE602007008553 D1 DE 602007008553D1
Authority
DE
Germany
Prior art keywords
disease
organic compounds
metabolic
dyslipdemia
errgamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007008553T
Other languages
English (en)
Inventor
Shamina M Rangwala
Susan C Stevenson
Zhidan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38477124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007008553(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602007008553D1 publication Critical patent/DE602007008553D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DE602007008553T 2006-05-03 2007-05-02 Verwendung von organischen verbindungen Active DE602007008553D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79722806P 2006-05-03 2006-05-03
PCT/US2007/067971 WO2007131005A2 (en) 2006-05-03 2007-05-02 Use of organic compounds

Publications (1)

Publication Number Publication Date
DE602007008553D1 true DE602007008553D1 (de) 2010-09-30

Family

ID=38477124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007008553T Active DE602007008553D1 (de) 2006-05-03 2007-05-02 Verwendung von organischen verbindungen

Country Status (13)

Country Link
US (1) US20090281191A1 (de)
EP (1) EP2015777B1 (de)
JP (1) JP2009535425A (de)
KR (1) KR20090005137A (de)
CN (1) CN101432024A (de)
AT (1) ATE477819T1 (de)
AU (1) AU2007248112A1 (de)
BR (1) BRPI0711174A2 (de)
CA (1) CA2649701A1 (de)
DE (1) DE602007008553D1 (de)
MX (1) MX2008014008A (de)
RU (1) RU2008147269A (de)
WO (1) WO2007131005A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
US8962546B2 (en) * 2011-03-01 2015-02-24 Salk Institute For Biological Studies Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3010587A4 (de) * 2013-06-18 2017-04-12 Salk Institute for Biological Studies Verfahren zur behandlung von muskeldystrophien
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
JP2017504650A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
EP3099677A4 (de) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidinbenzolsulfonderivate und verwendungen davon
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
CA2955077A1 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
EP3262157A4 (de) * 2015-02-27 2018-12-05 Salk Institute for Biological Studies Umprogrammierung von vorläuferzusammensetzungen und verfahren zur verwendung dafür
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044792A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazoldiazepines and uses thereof
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
WO2017053084A1 (en) * 2015-09-25 2017-03-30 Salk Institute For Biological Studies Estrogen related receptor gamma (erry) enhances and maintains brown fat thermogenic capacity
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
JP7178264B2 (ja) 2016-05-25 2022-11-25 ソーク インスティチュート フォー バイオロジカル スタディーズ オルガノイド作製および疾患モデル化のための組成物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1525323B1 (de) * 2001-11-09 2015-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1beta, ein neues pgc-1-homolog, und verwendungen dafür
JPWO2004015415A1 (ja) * 2002-08-08 2005-12-02 独立行政法人科学技術振興機構 薬剤スクリーニング方法
US20050074765A1 (en) * 2002-10-16 2005-04-07 Blanchard Steven G. Methods for identifying and using modulators of estrogen related receptor gamma
WO2006130503A2 (en) * 2005-05-27 2006-12-07 Janssen Pharmaceutica N.V. Errϝ peptide fragment complexes and uses thereof in drug discovery

Also Published As

Publication number Publication date
RU2008147269A (ru) 2010-06-10
BRPI0711174A2 (pt) 2011-08-23
ATE477819T1 (de) 2010-09-15
JP2009535425A (ja) 2009-10-01
EP2015777B1 (de) 2010-08-18
WO2007131005A2 (en) 2007-11-15
WO2007131005A3 (en) 2008-06-19
CN101432024A (zh) 2009-05-13
AU2007248112A1 (en) 2007-11-15
MX2008014008A (es) 2009-03-25
KR20090005137A (ko) 2009-01-12
CA2649701A1 (en) 2007-11-15
US20090281191A1 (en) 2009-11-12
EP2015777A2 (de) 2009-01-21

Similar Documents

Publication Publication Date Title
ATE477819T1 (de) Verwendung von organischen verbindungen
CY1118611T1 (el) Συνδυασμοι που περιεχουν παραγωγα της 6-βενζυλο-φαινυλο-2-θειοτετραϋδροπυραν-3,4,5-τριολης ως αναστολεις των συμμεταφορεων 1 και 2 νατριου-γλυκοζης για να χρησιμοποιηθουν σε διαβητικους ασθενεις
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
CL2007003264A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
EA201000050A1 (ru) Замещенные бициклолактамные соединения
WO2007104789A3 (en) Amylin derivatives
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
WO2008103354A3 (en) Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
MX2020003112A (es) Composiciones de biguanida y metodos para tratar trastornos metabolicos.
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
CL2007003183A1 (es) Compuestos biciclicos puenteados; y composicion farmaceutica, util para el tratamiento de trastornos del apetito, diabetes y obesidad entre otros.
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
EP2646032A4 (de) Therapeutische behandlung des stoffwechselsyndroms sowie von typ-2-diabetes, adipositas oder prädiabetes
EP1864976A4 (de) Propan-1,3-dionderivat oder salz davon